Home › Companies › REGENERON PHARMACEUTICALS INC. › 2023-2024
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and REGENERON PHARMACEUTICALS INC.’s Form 8-K, filed June 20, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 14, 2024: 8 items on REGENERON PHARMACEUTICALS INC.’s Form 8-K, filed June 20, 2024: 5 elected · 3 approved.
High dissent: 1 shareholder proposal (76.5% support).
Significant dissent: 1 director (27.9% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore REGENERON PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are REGENERON PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 20, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: N. Anthony Coles, M.D. | 110,481,731 | 1,873,397 | 99,413 | -- | 4,213,730 | 98% | Elected | — |
| Elect Director: Kathryn Guarini, Ph.D. | 111,988,738 | 359,659 | 106,144 | -- | 4,213,730 | 99.7% | Elected | — |
| Elect Director: Arthur F. Ryan | 81,009,658 | 31,288,101 | 156,782 | -- | 4,213,730 | 72% | Elected | — |
| Elect Director: George L. Sing | 102,751,205 | 9,574,839 | 128,497 | -- | 4,213,730 | 91% | Elected | — |
| Elect Director: David P. Schenkein, M.D. | 106,839,998 | 5,501,139 | 113,404 | -- | 4,213,730 | 95% | Elected | — |
| 2. Ratification of Appointment of Independent Registered Public Accounting Firm The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 | 111,350,016 | 5,257,636 | 60,619 | -- | -- | 95% | Approved | — |
| 3. Advisory Vote on Executive Compensation The resolution to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement on Schedule 14A filed April 25, 2024 | 106,667,264 | 5,579,814 | 207,463 | -- | 4,213,730 | 95% | Approved | — |
| 4. Non-Binding Shareholder Proposal Requesting Simple Majority Voting Requirements The non-binding shareholder proposal requesting simple majority voting requirements | 85,900,254 | 26,365,621 | 188,666 | -- | 4,213,730 | 77% | Approved | — |
Source: REGENERON PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 20, 2024 — read the filing on EDGAR.
See voting trends for Health Care companies, 2023-2024: shareholder support by sector and by company size.
1,003 asset managers disclosed a vote on at least one REGENERON PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 6 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: N. Anthony Coles, M.D.
REGENERON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: N. Anthony Coles, M.D.”): 110,481,731 for, 1,873,397 against, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The following nominees for Class III directors were elected to serve until the 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes: The following nominee for Class II director was elected to …”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 194 asset managers below reported 48,154,716 for, 642,137 against, 20,644 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 10,654,600 | 38,756 | 0 | 0 | For |
| Vanguard | 9,176,705 | 0 | 0 | 0 | For |
| Capital Group | 6,949,559 | 0 | 0 | 0 | For |
| JPMorgan | 4,786,814 | 0 | 0 | 0 | For |
| BlackRock | 3,230,718 | 561 | 0 | 0 | For |
| Dodge & Cox | 1,828,437 | 0 | 0 | 0 | For |
| Putnam | 1,308,906 | 0 | 0 | 0 | For |
| State Street | 1,115,775 | 45 | 0 | 0 | For |
| Invesco | 782,194 | 0 | 0 | 0 | For |
| American Century | 653,923 | 0 | 0 | 0 | For |
| Charles Schwab | 633,970 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,200 | 570,380 | 0 | 0 | Against |
| TIAA | 543,304 | 0 | 0 | 0 | For |
| AMCAP FUND | 527,034 | 0 | 0 | 0 | For |
| Dimensional | 492,148 | 0 | 0 | 0 | For |
| MFS | 352,388 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 327,042 | 0 | 0 | 0 | For |
| First Trust | 321,265 | 0 | 0 | 0 | For |
| Loomis Sayles | 299,985 | 0 | 0 | 0 | For |
| Jackson National | 222,330 | 186 | 0 | 0 | For |
| Equitable | 202,181 | 5,393 | 0 | 0 | For |
| PIONEER FUND /MA/ | 199,473 | 0 | 0 | 0 | For |
| Aberdeen | 167,165 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 165,274 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 164,727 | 0 | 0 | 0 | For |
Showing the 25 largest of 194 asset managers. All 194 are in the interactive database (link above).
Combines 7 wordings of this item as funds reported it.
99.7% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Kathryn Guarini, Ph.D.
REGENERON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Kathryn Guarini, Ph.D.”): 111,988,738 for, 359,659 against, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The following nominees for Class III directors were elected to serve until the 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes: The following nominee for Class II director was elected to …”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 194 asset managers below reported 48,796,836 for, 15 against, 20,644 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 10,693,356 | 0 | 0 | 0 | For |
| Vanguard | 9,176,705 | 0 | 0 | 0 | For |
| Capital Group | 6,949,559 | 0 | 0 | 0 | For |
| JPMorgan | 4,786,814 | 0 | 0 | 0 | For |
| BlackRock | 3,231,279 | 0 | 0 | 0 | For |
| Dodge & Cox | 1,828,437 | 0 | 0 | 0 | For |
| Putnam | 1,308,906 | 0 | 0 | 0 | For |
| State Street | 1,115,820 | 0 | 0 | 0 | For |
| Invesco | 782,194 | 0 | 0 | 0 | For |
| American Century | 653,923 | 0 | 0 | 0 | For |
| Charles Schwab | 633,970 | 0 | 0 | 0 | For |
| T. Rowe Price | 574,580 | 0 | 0 | 0 | For |
| TIAA | 543,304 | 0 | 0 | 0 | For |
| AMCAP FUND | 527,034 | 0 | 0 | 0 | For |
| Dimensional | 492,148 | 0 | 0 | 0 | For |
| MFS | 352,388 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 327,042 | 0 | 0 | 0 | For |
| First Trust | 321,265 | 0 | 0 | 0 | For |
| Loomis Sayles | 299,985 | 0 | 0 | 0 | For |
| Jackson National | 222,516 | 0 | 0 | 0 | For |
| Equitable | 207,574 | 0 | 0 | 0 | For |
| PIONEER FUND /MA/ | 199,473 | 0 | 0 | 0 | For |
| Aberdeen | 167,165 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 165,274 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 164,727 | 0 | 0 | 0 | For |
Showing the 25 largest of 194 asset managers. All 194 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
72% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Arthur F. Ryan
REGENERON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Arthur F. Ryan”): 81,009,658 for, 31,288,101 against, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The following nominees for Class III directors were elected to serve until the 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes: The following nominee for Class II director was elected to …”
Support: 72% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 194 asset managers below reported 39,078,171 for, 9,718,678 against, 20,647 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 8,495,109 | 2,198,247 | 0 | 0 | Mixed |
| Vanguard | 9,170,005 | 6,700 | 0 | 0 | For |
| Capital Group | 6,949,559 | 0 | 0 | 0 | For |
| JPMorgan | 4,786,814 | 0 | 0 | 0 | For |
| BlackRock | 3,227,666 | 3,613 | 0 | 0 | For |
| Dodge & Cox | 1,828,437 | 0 | 0 | 0 | For |
| Putnam | 1,308,906 | 0 | 0 | 0 | For |
| State Street | 224 | 1,115,596 | 0 | 0 | Against |
| Invesco | 0 | 782,194 | 0 | 0 | Against |
| American Century | 0 | 653,923 | 0 | 0 | Against |
| Charles Schwab | 0 | 633,970 | 0 | 0 | Against |
| T. Rowe Price | 4,200 | 570,380 | 0 | 0 | Against |
| TIAA | 543,304 | 0 | 0 | 0 | For |
| AMCAP FUND | 527,034 | 0 | 0 | 0 | For |
| Dimensional | 0 | 492,148 | 0 | 0 | Against |
| MFS | 0 | 352,388 | 0 | 0 | Against |
| INVESTMENT CO OF AMERICA | 327,042 | 0 | 0 | 0 | For |
| First Trust | 0 | 321,265 | 0 | 0 | Against |
| Loomis Sayles | 299,985 | 0 | 0 | 0 | For |
| Jackson National | 37,686 | 184,830 | 0 | 0 | Mixed |
| Equitable | 145,249 | 62,325 | 0 | 0 | Mixed |
| PIONEER FUND /MA/ | 0 | 199,473 | 0 | 0 | Against |
| Aberdeen | 0 | 167,165 | 0 | 0 | Against |
| MASTER INVESTMENT PORTFOLIO | 165,274 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 164,727 | 0 | 0 | 0 | For |
Showing the 25 largest of 194 asset managers. All 194 are in the interactive database (link above).
Combines 7 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: David P. Schenkein, M.D.
REGENERON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: David P. Schenkein, M.D.”): 106,839,998 for, 5,501,139 against, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The following nominees for Class III directors were elected to serve until the 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes: The following nominee for Class II director was elected to …”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 194 asset managers below reported 47,964,949 for, 831,903 against, 20,644 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 10,693,356 | 0 | 0 | 0 | For |
| Vanguard | 9,176,705 | 0 | 0 | 0 | For |
| Capital Group | 6,949,559 | 0 | 0 | 0 | For |
| JPMorgan | 4,786,814 | 0 | 0 | 0 | For |
| BlackRock | 3,229,443 | 1,836 | 0 | 0 | For |
| Dodge & Cox | 1,828,437 | 0 | 0 | 0 | For |
| Putnam | 1,308,906 | 0 | 0 | 0 | For |
| State Street | 1,115,781 | 39 | 0 | 0 | For |
| Invesco | 0 | 782,194 | 0 | 0 | Against |
| American Century | 653,923 | 0 | 0 | 0 | For |
| Charles Schwab | 633,970 | 0 | 0 | 0 | For |
| T. Rowe Price | 574,580 | 0 | 0 | 0 | For |
| TIAA | 543,304 | 0 | 0 | 0 | For |
| AMCAP FUND | 527,034 | 0 | 0 | 0 | For |
| Dimensional | 492,148 | 0 | 0 | 0 | For |
| MFS | 352,388 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 327,042 | 0 | 0 | 0 | For |
| First Trust | 321,265 | 0 | 0 | 0 | For |
| Loomis Sayles | 299,985 | 0 | 0 | 0 | For |
| Jackson National | 222,516 | 0 | 0 | 0 | For |
| Equitable | 207,157 | 417 | 0 | 0 | For |
| PIONEER FUND /MA/ | 199,473 | 0 | 0 | 0 | For |
| Aberdeen | 167,165 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 165,274 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 164,727 | 0 | 0 | 0 | For |
Showing the 25 largest of 194 asset managers. All 194 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
91% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: George L. Sing
REGENERON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: George L. Sing”): 102,751,205 for, 9,574,839 against, per its Form 8-K filed June 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The following nominees for Class III directors were elected to serve until the 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes: The following nominee for Class II director was elected to …”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 194 asset managers below reported 46,998,813 for, 1,798,041 against, 20,643 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 10,654,600 | 38,756 | 0 | 0 | For |
| Vanguard | 9,176,705 | 0 | 0 | 0 | For |
| Capital Group | 6,949,559 | 0 | 0 | 0 | For |
| JPMorgan | 4,786,814 | 0 | 0 | 0 | For |
| BlackRock | 3,230,718 | 561 | 0 | 0 | For |
| Dodge & Cox | 1,828,437 | 0 | 0 | 0 | For |
| Putnam | 1,308,906 | 0 | 0 | 0 | For |
| State Street | 553 | 1,115,267 | 0 | 0 | Against |
| Invesco | 782,194 | 0 | 0 | 0 | For |
| American Century | 653,923 | 0 | 0 | 0 | For |
| Charles Schwab | 633,970 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,200 | 570,380 | 0 | 0 | Against |
| TIAA | 543,304 | 0 | 0 | 0 | For |
| AMCAP FUND | 527,034 | 0 | 0 | 0 | For |
| Dimensional | 492,148 | 0 | 0 | 0 | For |
| MFS | 352,388 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 327,042 | 0 | 0 | 0 | For |
| First Trust | 321,265 | 0 | 0 | 0 | For |
| Loomis Sayles | 299,985 | 0 | 0 | 0 | For |
| Jackson National | 222,330 | 186 | 0 | 0 | For |
| Equitable | 202,181 | 5,393 | 0 | 0 | For |
| PIONEER FUND /MA/ | 199,473 | 0 | 0 | 0 | For |
| Aberdeen | 167,165 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 165,274 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 164,727 | 0 | 0 | 0 | For |
Showing the 25 largest of 194 asset managers. All 194 are in the interactive database (link above).
Combines 26 wordings of this item as funds reported it.
95% Approved · of votes cast
Prior year: 87.1% for (June 9, 2023 meeting) ▲ 7.9 pts
Description as filed by funds: Proposal to approve, on an advisory basis, executive compensation.
REGENERON PHARMACEUTICALS INC.’s own tally for this item (“3. Advisory Vote on Executive Compensation The resolution to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement on Schedule ”): 106,667,264 for, 5,579,814 against — passed, per its Form 8-K filed June 20, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3 – Advisory Vote on Executive Compensation The resolution to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement on Schedule 14A filed April 25, 2024 was approved based on the following votes:”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 10,693,356 | 0 | 0 | 0 | For |
| Vanguard | 9,176,705 | 0 | 0 | 0 | For |
| Capital Group | 6,949,559 | 0 | 0 | 0 | For |
| JPMorgan | 4,786,814 | 0 | 0 | 0 | For |
| BlackRock | 3,231,279 | 0 | 0 | 0 | For |
| Dodge & Cox | 1,828,437 | 0 | 0 | 0 | For |
| Putnam | 1,308,906 | 0 | 0 | 0 | For |
| State Street | 1,115,781 | 39 | 0 | 0 | For |
| Invesco | 782,194 | 0 | 0 | 0 | For |
| American Century | 653,923 | 0 | 0 | 0 | For |
| Charles Schwab | 633,970 | 0 | 0 | 0 | For |
| T. Rowe Price | 574,580 | 0 | 0 | 0 | For |
| TIAA | 543,304 | 0 | 0 | 0 | For |
| AMCAP FUND | 527,034 | 0 | 0 | 0 | For |
| Dimensional | 492,148 | 0 | 0 | 0 | For |
| MFS | 352,388 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 327,042 | 0 | 0 | 0 | For |
| First Trust | 321,265 | 0 | 0 | 0 | For |
| Loomis Sayles | 299,985 | 0 | 0 | 0 | For |
| Jackson National | 222,516 | 0 | 0 | 0 | For |
| Equitable | 207,574 | 0 | 0 | 0 | For |
| PIONEER FUND /MA/ | 199,473 | 0 | 0 | 0 | For |
| Aberdeen | 167,165 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 165,274 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 164,727 | 0 | 0 | 0 | For |
Fund voting reports, all 185 managers: 48,748,307 for, 13,891 against, 20,651 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 10,529,606 | 0 | 0 | 0 | For |
| Capital Group | 8,229,789 | 0 | 0 | 0 | For |
| JPMorgan | 7,503,508 | 1,504 | 0 | 0 | For |
| New York Life | 6,000,000 | 0 | 0 | 0 | For |
| BlackRock | 3,659,333 | 0 | 0 | 0 | For |
| State Street | 2,930,364 | 36,586 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,374,773 | 0 | 0 | 0 | For |
| Dodge & Cox | 2,234,393 | 0 | 0 | 0 | For |
| MCDONALD CAPITAL INVESTORS INC/CA | 1,363,499 | 0 | 0 | 0 | For |
| Putnam | 1,288,245 | 0 | 0 | 0 | For |
| Wellington | 1,047,505 | 0 | 0 | 0 | For |
| Invesco | 1,047,314 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,020,404 | 0 | 0 | 0 | For |
| Northern Trust | 969,091 | 6,952 | 0 | 0 | For |
| American Century | 755,040 | 0 | 0 | 0 | For |
| Amundi | 0 | 744,567 | 0 | 0 | Against |
| Charles Schwab | 699,557 | 0 | 0 | 0 | For |
| AllianceBernstein | 693,794 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 631,507 | 0 | 0 | 0 | For |
| Man Group plc | 625,250 | 0 | 0 | 0 | For |
| Legal & General Investment Management Ltd | 0 | 580,688 | 0 | 0 | Against |
| Nuveen | 561,963 | 0 | 0 | 0 | For |
| Neuberger Berman | 554,297 | 0 | 0 | 0 | For |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 540,646 | 0 | 0 | 0 | For |
| Vanguard | 457,697 | 0 | 0 | 0 | For |
Institutional-manager reports, all 851 managers: 66,642,313 for, 3,969,645 against, 2 withheld, 131 abstained, 4,023 not voted, 224 unknown. Showing the 25 largest; every one is in the interactive database (link above).
Combines 9 wordings of this item as funds reported it.
95% Approved · of votes cast
Prior year: 96.3% for (June 9, 2023 meeting) ▼ 0.8 pts
Description as filed by funds: Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.
REGENERON PHARMACEUTICALS INC.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Public Accounting Firm The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the ”): 111,350,016 for, 5,257,636 against — passed, per its Form 8-K filed June 20, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Ratification of Appointment of Independent Registered Public Accounting Firm The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024, was approved based upon the fol…”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 195 asset managers below reported 48,688,732 for, 116,596 against, 20,641 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 10,693,356 | 0 | 0 | 0 | For |
| Vanguard | 9,176,705 | 0 | 0 | 0 | For |
| Capital Group | 6,949,559 | 0 | 0 | 0 | For |
| JPMorgan | 4,786,814 | 0 | 0 | 0 | For |
| BlackRock | 3,231,279 | 0 | 0 | 0 | For |
| Dodge & Cox | 1,828,437 | 0 | 0 | 0 | For |
| Putnam | 1,308,906 | 0 | 0 | 0 | For |
| State Street | 1,115,781 | 39 | 0 | 0 | For |
| Invesco | 782,194 | 0 | 0 | 0 | For |
| American Century | 653,923 | 0 | 0 | 0 | For |
| Charles Schwab | 633,970 | 0 | 0 | 0 | For |
| T. Rowe Price | 574,580 | 0 | 0 | 0 | For |
| TIAA | 543,304 | 0 | 0 | 0 | For |
| AMCAP FUND | 527,034 | 0 | 0 | 0 | For |
| Dimensional | 492,148 | 0 | 0 | 0 | For |
| MFS | 352,388 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 327,042 | 0 | 0 | 0 | For |
| First Trust | 321,265 | 0 | 0 | 0 | For |
| Loomis Sayles | 299,985 | 0 | 0 | 0 | For |
| Jackson National | 222,516 | 0 | 0 | 0 | For |
| Equitable | 207,574 | 0 | 0 | 0 | For |
| PIONEER FUND /MA/ | 199,473 | 0 | 0 | 0 | For |
| Aberdeen | 167,165 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 165,274 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 164,727 | 0 | 0 | 0 | For |
Showing the 25 largest of 195 asset managers. All 195 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
77% Approved · of votes cast
Description as filed by funds: Non-binding shareholder proposal requesting simple majority voting requirements, if properly presented.
REGENERON PHARMACEUTICALS INC.’s own tally for this item (“4. Non-Binding Shareholder Proposal Requesting Simple Majority Voting Requirements The non-binding shareholder proposal requesting simple majority voting requirements”): 85,900,254 for, 26,365,621 against — passed, per its Form 8-K filed June 20, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 4 – Non-Binding Shareholder Proposal Requesting Simple Majority Voting Requirements The non-binding shareholder proposal requesting simple majority voting requirements was approved based upon the following votes:”
Support: 77% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of REGENERON PHARMACEUTICALS INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Adopt Simple Majority Vote” (9 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).
The 189 asset managers below reported 44,615,434 for, 723,796 against, 20,365 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 10,654,600 | 38,756 | 0 | 0 | For |
| Vanguard | 9,176,705 | 0 | 0 | 0 | For |
| Capital Group | 6,949,559 | 0 | 0 | 0 | For |
| JPMorgan | 4,786,814 | 0 | 0 | 0 | For |
| Dodge & Cox | 1,828,437 | 0 | 0 | 0 | For |
| Putnam | 1,308,906 | 0 | 0 | 0 | For |
| State Street | 1,115,596 | 224 | 0 | 0 | For |
| Invesco | 782,194 | 0 | 0 | 0 | For |
| American Century | 653,923 | 0 | 0 | 0 | For |
| Charles Schwab | 633,970 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,200 | 570,380 | 0 | 0 | Against |
| TIAA | 543,304 | 0 | 0 | 0 | For |
| AMCAP FUND | 527,034 | 0 | 0 | 0 | For |
| Dimensional | 492,148 | 0 | 0 | 0 | For |
| MFS | 352,388 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 327,042 | 0 | 0 | 0 | For |
| First Trust | 321,265 | 0 | 0 | 0 | For |
| Loomis Sayles | 299,985 | 0 | 0 | 0 | For |
| Jackson National | 222,330 | 186 | 0 | 0 | For |
| Equitable | 202,181 | 5,393 | 0 | 0 | For |
| PIONEER FUND /MA/ | 199,473 | 0 | 0 | 0 | For |
| Aberdeen | 167,165 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 164,727 | 0 | 0 | 0 | For |
| ProShares | 137,257 | 0 | 0 | 0 | For |
| Hartford | 134,871 | 0 | 0 | 0 | For |
Showing the 25 largest of 189 asset managers. All 189 are in the interactive database (link above).
Not shown here: this season’s fund filings also report 1 item from the meeting of June 9, 2023, which belongs to the 2022-2023 season; 1 item from the meeting of June 13, 2025, which belongs to the 2024-2025 season. A meeting outside this season’s July 1 to June 30 window is not counted in this page’s items or in its totals of asset managers and fund votes.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 107,800,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 9.92% |
| 2 | Vanguard | 8.51% |
| 3 | Capital Group | 6.45% |
| 4 | JPMorgan | 4.44% |
| 5 | BlackRock | 3.00% |
| 6 | Dodge & Cox | 1.70% |
| 7 | Putnam | 1.21% |
| 8 | State Street | 1.04% |
| 9 | Invesco | 0.73% |
| 10 | American Century | 0.61% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 9.77% |
| 2 | Capital Group | 7.63% |
| 3 | JPMorgan | 6.96% |
| 4 | New York Life | 5.57% |
| 5 | BlackRock | 3.39% |
| 6 | State Street | 2.75% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 2.20% |
| 8 | Dodge & Cox | 2.07% |
| 9 | MCDONALD CAPITAL INVESTORS INC/CA | 1.26% |
| 10 | Putnam | 1.20% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| FMR LLC | 10,317,407 | 9.57% | Proxy statement (DEF 14A), proxy filed April 25, 2024 |
| The Vanguard Group, Inc. | 8,838,240 | 8.20% | Proxy statement (DEF 14A), proxy filed April 25, 2024 |
| BlackRock, Inc. | 8,629,707 | 8.01% | Proxy statement (DEF 14A), proxy filed April 25, 2024 |
| JPMorgan Chase & Co. | 7,219,436 | 6.70% | Proxy statement (DEF 14A), proxy filed April 25, 2024 |
| State Street | 4,841,548 | 4.49% | Form 13F, quarter ended March 31, 2024 |
| Capital International | 3,129,010 | 2.90% | Form 13F, quarter ended March 31, 2024 |
| Geode Capital | 2,376,591 | 2.20% | Form 13F, quarter ended March 31, 2024 |
| Leonard S. Schleifer, M.D., Ph.D. | 1,726,565 | 1.60% | Proxy statement (DEF 14A), proxy filed April 25, 2024 |
| Franklin Templeton | 1,694,298 | 1.57% | Form 13F, quarter ended March 31, 2024 |
| Morgan Stanley | 1,450,972 | 1.35% | Form 13F, quarter ended March 31, 2024 |
Percentages above are of 107,800,000 shares outstanding, as reported by REGENERON PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At REGENERON PHARMACEUTICALS INC.'s shareholder meeting held June 14, 2024, in the 2023-2024 proxy season, 1,003 asset managers reported votes on at least one of its 8 ballot items in their SEC Form N-PX filings, covering 9,907 separate fund positions. On the most widely held item on that ballot — Proposal to approve, on an advisory basis, executive compensation. — REGENERON PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 95% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: REGENERON PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 20, 2024.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from REGENERON PHARMACEUTICALS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
REGENERON PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Proxy Votes Now, “REGENERON PHARMACEUTICALS (REGN) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/regeneron-pharmaceuticals-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.